Moderna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 Shares

Posted by Teresa Graham on Jun 18th, 2026

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

On Friday, May 15th, Stephen Hoge sold 53,336 shares of Moderna stock. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40.

Moderna Stock Performance

NASDAQ:MRNA opened at $61.80 on Thursday. The firm has a 50 day simple moving average of $50.05 and a 200-day simple moving average of $44.83. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The firm has a market cap of $24.52 billion, a PE ratio of -7.58 and a beta of 1.05. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $62.30.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s quarterly revenue was up 260.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.52) EPS. On average, equities analysts expect that Moderna, Inc. will post -6.51 EPS for the current year.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Assetmark Inc. increased its position in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares in the last quarter. New Mexico Educational Retirement Board increased its position in shares of Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after acquiring an additional 300 shares in the last quarter. Cromwell Holdings LLC increased its position in shares of Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares in the last quarter. IFP Advisors Inc increased its position in shares of Moderna by 5.4% in the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after acquiring an additional 348 shares in the last quarter. Finally, Empowered Funds LLC increased its position in shares of Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock worth $405,000 after acquiring an additional 353 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on MRNA shares. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Royal Bank Of Canada upped their price target on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research report on Monday, May 4th. Barclays upped their price target on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Finally, UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $36.60.

Check Out Our Latest Report on Moderna

More Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: FDA briefing materials and staff comments were more constructive than feared on Moderna’s mRNA flu vaccine, suggesting data may support effectiveness in adults 65 and older and easing concerns ahead of the advisory-panel vote on whether the shot’s benefits outweigh its risks. Article: US FDA staff says data may support effectiveness of Moderna’s flu vaccine in older adults
Positive Sentiment: Investors are also reacting to Moderna’s preparations for potential product launches, including leadership and organizational changes that strengthen commercialization efforts for 2027–2028 pipeline opportunities. Article: Moderna announces executive changes ahead of potential launches
Positive Sentiment: Moderna said it will host an Investor Event/Science Day on June 25, giving bulls another near-term catalyst to watch for pipeline updates and strategic messaging. Article: Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
Neutral Sentiment: The FDA advisory committee is still set to scrutinize the flu vaccine’s risk-benefit profile, so the stock may remain volatile until the vote is complete. Article: Moderna’s mRNA flu vaccine faces FDA advisory panel scrutiny
Negative Sentiment: One potential overhang is insider selling: President Stephen Hoge sold shares earlier this week, though the transaction was made under a pre-arranged trading plan and does not necessarily signal a change in fundamentals. Article: Moderna, Inc. (NASDAQ:MRNA) – Get Free Report

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.